Menu Search
Equities

Control Bionics Ltd

CBL:ASX

Control Bionics Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.066
  • Today's Change0.001 / 1.54%
  • Shares traded612.00
  • 1 Year change+32.00%
  • Beta0.8091
Data delayed at least 20 minutes, as of Nov 15 2024 00:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Control Bionics Ltd was unable to grow net income despite reducing the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percent of sales). Net income shrank 5.02% from a loss of 5.63m to a larger loss of 5.91m despite revenues that were relatively flat.
Gross margin75.62%
Net profit margin-99.13%
Operating margin-98.26%
Return on assets-66.73%
Return on equity-88.16%
Return on investment-85.40%
More ▼

Cash flow in AUDView more

In 2024, Control Bionics Ltd did not generate a significant amount of cash. Cash Flow from Financing totalled 5.43m or 90.02% of revenues. In addition the company used 4.91m for operations while cash used for investing totalled 473.09k.
Cash flow per share-0.0318
Price/Cash flow per share--
Book value per share0.0315
Tangible book value per share0.0111
More ▼

Balance sheet in AUDView more

Control Bionics Ltd has a Debt to Total Capital ratio of 13.30%, a higher figure than the previous year's 0.88%.
Current ratio1.57
Quick ratio1.40
Total debt/total equity0.1535
Total debt/total capital0.133
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.